Obesity shapes metabolism in the tumor microenvironment to suppress anti-tumor immunity
Obesity shapes metabolism in the tumor microenvironment to suppress anti-tumor immunity Obesity has become a global health concern, with its impacts extending beyond metabolic disorders to influence cancer progression and treatment outcomes. Recent research has uncovered a compelling link between obesity, tumor microenvironment (TME) modulation, and immune suppression, revealing that excess adiposity can fundamentally alter the metabolic landscape of tumors, thereby blunting the body’s natural anti-tumor defenses.
The tumor microenvironment is a complex ecosystem composed of cancer cells, immune cells, stromal cells, blood vessels, and extracellular matrix components. This environment plays a crucial role in tumor growth, metastasis, and response to therapies. Obesity introduces an additional layer of complexity by modifying the metabolic profile within this niche. Adipose tissue, especially in obese individuals, secretes a plethora of cytokines, adipokines, and free fatty acids, which infiltrate the TME and influence cellular behavior. These factors can shift the metabolic balance, favoring tumor survival and immune evasion.
One key aspect of this metabolic reprogramming involves the increased availability of fatty acids and glucose in obese individuals. Tumor cells adapt by enhancing their glycolytic activity—known as the Warburg effect—and lipid metabolism, providing essential energy supplies for rapid proliferation. However, this metabolic shift does not just benefit cancer cells; it also impacts immune cells within the TME. For example, the heightened fatty acid levels can impair the function of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, which are critical for orchestrating anti-tumor immune responses. These immune cells rely on specific metabolic pathways for activation and effector functions, and lipid overload can induce exhaustion or anergy, reducing their ability to attack tumor cells effectively.
Furthermore, obesity-induced metabolic alterations promote the accumulation of immunosuppressive cell populations, such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs). These cells further dampen immune responses through the secretion of suppressive cytokines and direct cell-cell interactions. The metabolic environment fostered by obesity also leads to increased expression of immune checkpoint molecules like PD-L1 on tumor and immune cells, further inhibiting effective immune surveillance.
These insights underscore that obesity does more than just increase cancer risk; it actively reshapes the metabolic and immune landscape of tumors to favor immune escape. Targeting these metabolic pathways presents a promising avenue for enhancing immunotherapy efficacy in obese patients. Strategies might include metabolic modulators that restore immune cell function or inhibit lipid uptake by tumor cells, thereby reactivating anti-tumor immunity.
In conclusion, obesity’s impact on tumor metabolism and immunity is profound and multifaceted. Understanding these interactions offers new opportunities to develop tailored therapies that can overcome obesity-driven immune suppression, ultimately improving outcomes for cancer patients with obesity.
